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The brain is the most complex organ in the body, controlling our highest functions,
as well as regulating myriad processes which incorporate the entire physiological
system. The effects of prospective therapeutic entities on the brain and central
nervous system (CNS) may potentially cause significant injury, hence, CNS toxicity
testing forms part of the “core battery” of safety pharmacology studies. Drug-induced
seizure is a major reason for compound attrition during drug development. Currently,
the rat ex vivo hippocampal slice assay is the standard option for seizure-liability
studies, followed by primary rodent cultures. These models can respond to diverse
agents and predict seizure outcome, yet controversy over the relevance, efficacy,
and cost of these animal-based methods has led to interest in the development of
human-derived models. Existing platforms often utilize rodents, and so lack human
receptors and other drug targets, which may produce misleading data, with difficulties
in inter-species extrapolation. Current electrophysiological approaches are typically
used in a low-throughput capacity and network function may be overlooked. Human-
derived induced pluripotent stem cells (iPSCs) are a promising avenue for neurotoxicity
testing, increasingly utilized in drug screening and disease modeling. Furthermore,
the combination of iPSC-derived models with functional techniques such as multi-
electrode array (MEA) analysis can provide information on neuronal network function,
with increased sensitivity to neurotoxic effects which disrupt different pathways. The
use of an in vitro human iPSC-derived neural model for neurotoxicity studies, combined
with high-throughput techniques such as MEA recordings, could be a suitable addition
to existing pre-clinical seizure-liability testing strategies.
Keywords: iPSC neurons, astrocytes, seizures, in vitro, safety pharmacology
SEIZURES
The brain is vulnerable to damage by physical trauma and a multitude of injurious agents, including
pathogens, pharmaceuticals, and toxins. Physiological and anatomical protection and regulation
for the controlled environment of the brain is provided by the blood–brain barrier (BBB). This
consists of brain endothelia, astrocytes, and pericytes, providing a system of tight endothelial
junctions where selective permeability to water, some gases, and fuel sources such as glucose and
amino acids can be modulated (Daneman and Prat, 2015). This separation of the brain from
the systemic blood circulation maintains comprehensive and minute control of its biochemistry,
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especially via glial cells which regulate the ionic and nutrient
composition of fluid surrounding neurons (Prat et al., 2001).
Should these mechanisms fail, the risk of brain injury is increased.
Indeed, seizure is one such severe neurological complication that
can present either as a result of an adverse drug reaction (ADR),
infection, or from trauma (Vaughan and Delanty, 2002; Koseki
et al., 2014).
A seizure is the defining symptom of epilepsy, which is
one of the most common chronic neurological disorders,
estimated to affect 65 million individuals worldwide (Thurman
et al., 2011). “Epilepsy” encompasses multiple syndromes which
predispose the individual to generation of epileptic seizures
(Fisher et al., 2005). A seizure itself is defined as an abnormal,
transient discharge of neurons in the brain (Fisher et al., 2005),
and is broadly characterized by neuronal hyperexcitability and
hypersynchrony (Jiruska et al., 2013). If an individual suffers a
single event with no recurrence, they are said to have suffered
a seizure. If multiple consecutive and/or recurring seizures
are experienced, the patient may be diagnosed with epilepsy
(Scharfman, 2007). Furthermore, “epileptogenesis” describes the
processes which render a healthy system capable of generating
seizures, whilst also establishing the condition, hence making
recurrent seizures more likely (Pitkänen, 2010). Patients suffering
from seizures experience different effects depending on the
brain region involved. These may include changes in cognition,
paresthesia, or the experience of flashing lights or unusual odors.
Convulsions are commonly observed, which can be accompanied
by various combinations of muscle rigidity (tonic) and jerking
limb (clonic) activity.
Although seizure is the defining symptom of the epilepsies,
only about 25% of patients who suffer seizure have an epilepsy
syndrome (Stasiukyniene et al., 2009). The remaining patients
suffer seizures from the major causes listed above, as well as
neonatal occurrences among infants. These seizures may be
described as provoked or acute symptomatic, as they are not the
result of established or enduring brain alterations, but rather
occur in an acute and transient manner (Fisher et al., 2005;
Thurman et al., 2011). The potential severity of seizures makes
them an important metric for neurotoxicity assays.
WHAT DO WE EXPECT FROM IN VITRO
MODELS OF SEIZURE-LIABILITY
TESTING?
Central nervous system (CNS) toxicity testing of any new
pharmaceutical is a vital procedure and legal requirement
for safety pharmacology studies (ICH, 2000). A drug-induced
seizure is an example of a potentially fatal ADR and is the
most commonly encountered CNS-related issue during the
drug development process (Authier et al., 2016). Pre-clinical
seizure-liability (PSL) testing is essential to identify such ADRs;
however, these tests usually occur late in the drug development
process (Figure 1; Easter et al., 2007). Despite the severity of
drug-induced seizure, there are no official guidelines outlining
how this issue should be tested and regulated (Easter et al.,
2009). In vitro models enable potential side effects to be
FIGURE 1 | The drug-development process. Taking anywhere up to 15 years
and a cost of ∼$1.7 billion, the process can be separated into pre-clinical and
clinical testing. Pre-clinical studies consist of in silico, in vitro, and in vivo
animal and cell-based assays. Post-market surveillance continues indefinitely
(Mundae and Östör, 2010). Reducing these studies or finding better
alternatives can save time, cost, and resources.
discovered earlier, thereby saving time, cost, and resources.
However, current models are hindered by limitations such as low-
throughput capabilities, arguable relevance to man and a heavy
reliance on animal studies, which often require considerable
expense. Furthermore, in vivo PSL testing frequently requires
specialist practitioners, also likely to increase costs and decrease
throughput.
An ideal model system for in vitro PSL testing should be
able to recapitulate the information existing models provide and
address some of their limitations. The most obvious shortcoming
for current platforms is that they use animals. An ideal platform
would therefore be relevant to humans, through the use of
cells which are anatomically human, expressing human receptor
proteins with which current convulsant and anti-convulsant
compounds can interact. The cells should also be able to
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form functional neurophysiological networks, containing the
various cell types seen in the intact brain. Importantly, the
platform must be capable of pharmacological interrogation,
of displaying phenotypic human seizure-like activity and of
sensitivity to known therapeutic anti-convulsants. The system
should also be robust and amenable to high-throughput
testing and predictive of the effects of diverse neuroactive
compounds.
Current effective in vitro models include rodent brain
tissue slices and CNS cell cultures. These have been
employed for decades and are credited with the discovery
of mechanisms pertinent to seizure, epilepsy, and neurobiology
in general. Animal-based models of seizure are important
for defining epileptiform and seizure activity, creating
standards and descriptions to which the field can relate
their findings. While “seizure” describes a full seizure event
in vivo, the term “seizure-like event” (SLE) more accurately
describes the effects seen in in vitro and predictive in silico
models. A human-based in vitro seizure-liability platform
should fundamentally be capable of generating human
SLEs.
CURRENT IN VITRO MODELS OF
SEIZURE
There are many models for seizure-liability testing to choose
from. For simplicity, the following section will focus on the
models most commonly used in toxicity screening and a
comparison of these models is shown in Table 1.
Acute Slice Assays
In a 2016 industrial survey of nervous system safety
pharmacology, the rat ex vivo hippocampal slice (HS) assay
was found to be most commonly used for seizure-liability
testing (Authier et al., 2016). Slices can be obtained from any
region of any species with a complex brain. HSs make for
useful in vitro models as they retain a defined cytoarchitecture
and relevant receptors and constituents of the full brain
system, including inter-area connectivity. This is of great
importance, as the cause of seizures and epileptiform activity
can be complex and interlinked with multiple hierarchical
levels of the CNS (Scharfman, 2007). External conditions can
be precisely controlled and manipulated with HSs. Indeed,
slice assays typically involve manipulation of the extracellular
ionic milieu to induce SLE, as discussed in Section “Inducing
Seizure-Like Events Using in vitro Models.” Furthermore,
the mechanisms by which different agents induce SLE is
highly variable. With tissue slices, there is a greater likelihood
that all necessary cell types and receptors to respond to
diverse pharmacological agents are present. Acute slices are
harvested from adult rodent brain, intended for experimentation
on the same day to study individual neurons or neuronal
circuits (Lein et al., 2011). However, difficulties in inter-
species extrapolation reduce the utility of the platforms and
inevitably, slice preparations undergo important cellular and
environmental changes including ischemia and severing of
projection neurons that would have connected the slice to the
rest of the system. Obviously, human brain tissue is problematic
to obtain (except for limited excised epileptic tissue), so
efforts to refine the commonly used rodent HS or replace
TABLE 1 | Comparison of current major seizure-liability testing models with proposed iPSC-derived model.
Model Benefits Limitations
Acute slice assay rRepresentative of in vivo rodent adult brain rDifficulty in inter-species extrapolationrSame day experimentation rPreparations undergo cellular changes and damagerValidated for use rProjection neurons severedrDefined cytoarchitecture rTypically low throughputrCurrent ‘gold standard’rForms functional network
Organotypic slice culture rRepresentative of in vivo rodent rDifficulty in inter-species extrapolationrRetain connective properties of the tissuerCan recover from damage from slicingrCan assess long-term effects of neuroactive chemicalsrForms functional network
rDerived from neonates, so may not be predictive of matured
systemrMore time consumingrRequires supportive culture mediumrSynaptic reorganization/remodeling
Primary CNS culture rRepresentative of cell subtypes in vivo rDifficulty in inter-species extrapolationrPredictive model validated rLoss of structure and 3-dimensionalityrHigher throughput than slices rMore time consumingrDo cultured cells reach maturity?rOften cultured in absence of astrocytes or other neural cells
iPSC-derived culture rHuman-based rExpensiverExhibit humanoid morphology rTime consumingrRetain genotype of original fibroblast, so can be used to
model genetic components of epilepsy from patients
with specific mutationsrAmenable to increased throughputrNo ethical considerations
rResearch still in infancy, lacking validationrNo defined ultrastructurerNo guarantee of presence of desired cell typesrNo standard protocol
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with non-human primates have been attempted (Easter et al.,
2007). Once removed from the animal, slices rapidly begin to
deteriorate, making them an expensive and low-throughput
model system; however, a semi-automated platform has been
validated for use in pre-clinical testing, allowing multiple
slices per animal to be perfused simultaneously, and hence,
increasing the throughput capabilities of the platform (Easter
et al., 2007).
Organotypic Slice Assays
In contrast to acute slice preparations, organotypic slices (OS)
are derived from neonatal rodents and are maintained in vitro
for several weeks (Lein et al., 2011). Compared with acute
slices, OS require more time and resources, particularly a
culture medium which can provide essential growth factors,
hormones and metabolites; which may or may not include
serum. As variability between culture media can frequently
be attributed to serum, chemically defined media have also
been developed and have been shown to support OS culture
and more importantly facilitate seizurogenesis (Liu et al.,
2017).
Organotypic slices are representative of their respective
in vivo counterpart. They contain most of the neuronal
subtypes present in the brain and retain intrinsic connective
properties of the tissue. As previously mentioned, excision
of acute slices leads to cellular damage, ischemia, and an
altered metabolic state; however, OS can recover from these
insults during culture. Furthermore, any necrotic cells or debris
disappears after several weeks in culture (Lein et al., 2011).
OS are particularly useful for assessing long-term effects of
agents or SLEs, as they can be further incubated following
experimentation.
Despite the supposed benefits of OS, there are limitations
in using them as models, cf acute slices. There is concern
that as the tissue is harvested from neonates, this is not
entirely representative of adult tissue. While any acute
damage to OS rectifies itself, synaptic reorganization
and axonal/dendritic remodeling can occur because of
deafferentation (Gutiérrez and Heinemann, 1999). The
trauma of slicing can also activate glial cells, leading to
the formation of an astrocytic scar, which was believed to
influence the prevention of axon regeneration, although
now this is disputed (Lein et al., 2011; Anderson et al.,
2016).
Primary Cell Culture Assays
The second most commonly used model system for seizure-
liability studies is primary neuronal cell cultures (Authier et al.,
2016). Similarly to slice models, primary rodent CNS cultures
can contain most, if not all, of the components of intact cortex,
which bear a true resemblance to the cells in vivo. However, the
structure and three-dimensional nature of the brain is lost. Unlike
slice assays, cell cultures are typically higher throughput, but do
take several weeks in culture to reach maturity, as is the case
with OS.
While neurons are an absolute requirement for seizure
activity, they are not the only cell type involved. Indeed, omitting
other cell types, or culturing ratios of subtypes not representative
of in vivo ratios could affect the validity of such models. There is
also concern that certain receptors or channels may not appear in
cultured neurons, which may or may not influence the outcome
of experiments (Dichter and Pollard, 2006). In spite of this,
primary cell culture assays can reliably and consistently predict
seizure liability. Bradley et al. (2018) have recently published a
comprehensive in vitro screen for seizure liability using primary
rat cortical neurons, including ratios of neurons and astrocytes
observed in the intact rat brain (Bradley et al., 2018). In addition,
Kreir et al. (2018) have also illustrated the predictive capability
of rat cortical models from cultures containing both excitatory
and inhibitory neuronal subtypes (Kreir et al., 2018). These
rodent cells can respond to a large group of agents known
to induce SLEs, with consideration of multiple neural activity
markers (Bradley et al., 2018; Kreir et al., 2018). However, like
OS, there is controversy over when the cultured cells reach
maturity, and at which point they should be used for seizure-
liability studies so that they are as representative of the living
system as possible. Arguably, the most important consideration
for epileptiform studies is the capability of cells to evolve
network functionality, which can develop, propagate, and sustain
SLEs.
Astrocytes and Their Role in Seizure
Many studies of seizures describe properties of neuronal
cells and networks. However, glial cells such as: astrocytes,
oligodendrocytes, microglia, and Schwann cells perform vital
support tasks in the nervous system. Within the CNS, numbers
of glial cells have been overestimated in the past, and it has
been shown that the neuron:glia ratio varies throughout areas
of the brain (von Bartheld et al., 2016). In the cerebellum,
glial cells make up only 18.9% of cells, while in the rest of
brain, this figure increases to 91.7% (Herculano-Houzel, 2014).
Despite this significant quantity, it is only relatively recently that
astrocytes have been studied in sufficient depth to appreciate the
full diversity of their roles in the brain.
Excessive glutamatergic excitation of neurons can cause
excitotoxicity, resulting in damage to, and the eventual death
of the neuron (Maragakis et al., 2004). Astrocytes take up
excess ammonia and glutamate from the synaptic cleft via
the GLT1 (EAAT2) transporter (Maragakis et al., 2004)
and use glutamine synthetase to convert it to glutamine
via a condensation reaction (Choi, 1987). Inhibition of
astrocytic glutamine synthetase has been implicated in
multiple neurodegenerative disorders, including epilepsy
(Eid et al., 2013). Furthermore, GLT1 knockout rats have an
increase in neuronal cell death and in extracellular glutamate
concentration, characteristic of excitotoxicity (Rothstein et al.,
1996).
In addition to glutamate, healthy astrocytes also balance
potassium levels. During AP discharge, extracellular K+
increases, with the concentration increasing considerably
during seizure (Feldberg and Sherwood, 1957). Accumulation
of extracellular K+ would lead to the resting membrane
becoming more positive, affecting gating of ion channels,
transporters, and various receptors. Astrocyte membranes
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are highly permeable to potassium with many potassium
channels along with sodium/potassium ATPases, and so
prevent against such events (Carmignoto and Haydon, 2012).
In rodent models, these transporters are responsible for
maintaining low extracellular K+ levels and importantly,
restore resting levels of K+ following epileptiform activity
(Coulter and Steinhauser, 2015). Dysfunction to astrocytic
uptake of extracellular K+ and astrocytic uncoupling can lead
to the generation and propagation of seizure (Bedner et al.,
2015).
Human Tissue
Although the focus of this review is on models for drug-induced
seizures, research using resected human tissue from patients with
drug-resistant epilepsy should be considered. The possibilities
for human tissue range from histopathological analyses, to
modulation of SLE in drug-resistant tissue and the testing
of novel anti-convulsant compounds and electrophysiological
investigation (Gabriel et al., 2004; Hsiao et al., 2015; Jones et al.,
2016; Klaft et al., 2016). Furthermore, a number of methods
are now available that increase the longevity of the resected
tissue, enabling increased throughput of investigations (Schwarz
et al., 2017; Wickham et al., 2018). However, it is unlikely that
a sufficient amount of human tissue will ever be available for
high-throughput compound screening. Furthermore, the tissue
is often in a diseased state, which may demonstrate different
responses to otherwise healthy tissue. Ethical considerations and
consent also need to be obtained to use human tissue, further
complicating an already limited process. Human stem cells could
provide a viable alternative to human tissue, allowing researchers
to generate functional neuronal networks for high-throughput
drug testing.
iPSCs
Induced pluripotent stem cell (iPSC) technology (Takahashi and
Yamanaka, 2006) has considerable potential for toxicity testing
and disease modeling, allowing the generation, growth, and
study of human cells without the need for invasive isolation
procedures or extensive ethical approval. The application of
iPSCs extends from neurotoxicity testing and disease modeling to
drug-screening and cell-based therapies (Jung et al., 2012; Kumar
et al., 2012; Pei et al., 2016).
Neuronal cultures which are derived from human iPSC could
be a suitable addition to PSL testing, as the systems are closer to
humans than a primary rodent-derived cell line. In fact, human
iPSCs are very similar to embryonic stem cells (Robinton and
Daley, 2012). In addition, a remarkable benefit of iPSCs is that
they retain the genotype of the original fibroblast cell and indeed,
any cell then generated from iPSCs also shares that genetic
background. This is invaluable in disease research, as cells taken
from both patients and controls can be studied and compared.
iPSC-Derived Seizure-Liability Models
The foremost aim of in vitro neurotoxicity tests, including
iPSC-derived PSL models, should be to replicate the in vivo
morphology and functionality as closely as possible. Diseases of
the cerebral cortex are major causes of morbidity and mortality.
Hence, iPSC-derived cortical neuronal systems may provide a
reliable predictive base for PSL testing and are conceptually more
relevant to toxicity testing than animal tissue, as they are human
cells. Protocols for the development of iPSC-derived cortical
neurons and characterization of cortical neurogenesis and
terminal differentiation to achieve mature electrophysiological
properties and functional excitatory synapses have been
developed, as shown in Figure 2 (Chambers et al., 2009; Shi
et al., 2012a; Gunhanlar et al., 2018). The development of
iPSC-derived cortical cultures should demonstrate the presence
of cortical neuronal markers, astrocytes, and populations of
excitatory and inhibitory neurons, (which exist at roughly
80–20% in the human cortex, respectively). Indeed, the cortical
induction method proposed by Shi et al. (2012b) showed the
generation of astrocytes following spontaneous differentiation.
Moreover, it has been shown that human iPSCs can also be
differentiated exclusively into astrocytes (Shaltouki et al., 2013)
and interneurons (Liu et al., 2013; Kim et al., 2014). This is of
critical importance when considering the seizurogenic potential
of novel compounds. An entirely excitatory or inhibitory
culture is not a representative system and true responses to
novel compounds may not be accurately observed without
inclusion of both major neural subtypes. Indeed, Tukker et al.
(2018) have reported that known seizurogenic agents may not
display typical reponses in cultures of iPSC-derived neurons
and astrocytes, where there is an unnatural ratio of excitatory
to inhibitory neurons (Tukker et al., 2018). In addition,
significant differences in drug responses have been reported
between different iPSC-derived neuronal cells, highlighting the
importance of mixed cultures (Pei et al., 2016). Efforts have been
made to determine the presence of excitatory and inhibitory
neuronal populations and neuron/astrocyte ratios and it would
appear that immunocytochemical staining for morphological
assessment and pharmacological interrogation are valid methods
to suggest the presence/absence of such neuronal subtypes and
astrocytes (Kuijlaars et al., 2016; Tukker et al., 2016; Gunhanlar
et al., 2018; Tukker et al., 2018). While excitatory and inhibitory
iPSC-derived neural cells and iPSC-derived astrocytes can now
be commercially obtained, the key to a healthy responsive system
is the balance (and presence) of these specific subtypes in a
given culture. A complete, demonstrative, heterogenous system
must include all subtypes and at ratios close to those observed
in vivo.
iPSC-Derived Astrocytes in a Cortical
Model of Seizure Liability
Neurons cannot function in vivo without astrocytes. Among their
many functions, astrocytes are highly involved in the formation
and maturation of excitatory and inhibitory synapses in the CNS,
and also their degradation and removal to refine neural circuits
(Nguyen et al., 2011). For example, rodent retinal ganglion cells
form very few synapses when cultured alone, but the number
is increased 10-fold in the presence of astrocytes or astrocyte-
conditioned media (ACM; Pfrieger and Barres, 1997).
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FIGURE 2 | Schematic of iPSC-derived neuronal and glia cell generation from fibroblast cells. Patient fibroblasts are reprogrammed with master regulators of
pluripotency: c-Myc, OCT4, Klf-4, and SOX2. iPSC colonies are formed, which via a process known as dual-SMAD inhibition can induce the iPSCs to a neural fate.
Following neural precursor cell formation, radial glia-like cells are produced which differentiate over time into neurons and astrocytes.
Several studies using iPSC-derived neural models have co-
cultured human iPSC-derived neurons together with rodent
astrocytes or ACM (Tang et al., 2013; Odawara et al., 2014,
2016a,b). The differences between rodent and human astrocytes
are quite considerable, ranging from their size and function
to the presence of morphologically distinct astrocyte subtypes
within the human brain and the cortex in particular (Oberheim
et al., 2009). However, studies using iPSC neurons and
rodent astrocytes have highlighted the importance of including
astrocytes in culture. Human-neuronal and rodent-astrocytic co-
cultures demonstrate enhanced functional maturation, spiking
activity, and maintenance of long-term electrical activity cf
neurons alone (Odawara et al., 2014; Lischka et al., 2018). It
has recently been suggested that co-culture of human neurons
with rodent astrocytes may generate matured spontaneous
electrical activity to a greater extent than using human
astrocytes (Lischka et al., 2018). However, this may reflect the
relative maturity of iPSC- derived astrocytes used in these
studies.
Studies of stem cell-derived astrocytes have demonstrated
that these cells are capable of exhibiting many of the
functions of human in vivo astrocytes, including: facilitating
synaptic maturation, gliotransmission, protection of neurons
from excitotoxicity and stress, and astrocytic calcium activity
(Hill et al., 2016). An increasing number of studies have seeded
iPSC-derived neurons with human iPSC-derived astrocytes in
short-term cultures (Tukker et al., 2016, 2018; Kayama et al.,
2018; Matsuda et al., 2018) and with a specific focus on
neurotoxicity testing and seizure-liability testing (Ishii et al.,
2017; Tukker et al., 2018). It has been demonstrated that iPSC-
derived neural co-cultures are capable of generating epileptiform
activity in response to convulsants (Ishii et al., 2017), and that
network activity, bursting activity, and synchronicity is facilitated
by the inclusion of human iPSC-derived astrocytes (Tukker et al.,
2018). However, a full characterization and validation of seizure-
liability, similar to the acute slice work of Easter et al. (2007), is
yet to be performed using iPSC-derived systems. Furthermore,
assessing the effects of compounds on astrocytes will provide
increased accuracy and validity, particularly as astrocyte-specific
agents can be tested and monitored in mixed cultures (Hill et al.,
2012).
Co-culturing iPSC-derived neuronal cells with astrocytes
ensures the development of a heterogenous neural model. The
inclusion of astrocytes is important, as astrocyte dysfunction
may be involved in seizure activity, as discussed in Section
“Astrocytes and Their Role in Seizure.” However, there are a
variety of ways to generate these cultures. During in vivo brain
development, astrocyte differentiation follows radial glia and
neuronal differentiation (Figure 2). To our knowledge, no study
has attempted to generate co-cultures following this spontaneous
differentiation protocol, for the express purposes of seizure-
liability testing. It would be of great interest to determine any
differences in the predictivity of cultures generated by seeding
neuronal cells and astrocytes together (Kuijlaars et al., 2016;
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Tukker et al., 2016, 2018; Ishii et al., 2017; Kayama et al., 2018,
Matsuda et al., 2018), compared to spontaneous differentiation
(Shi et al., 2012a,b; Kirwan et al., 2015; Kuijlaars et al., 2016;
Gunhanlar et al., 2018; Paavilainen et al., 2018), wherein mixed
populations of neurons and astrocytes are generated. The
spontaneous route is not as rapid, with emergence of astrocytes
seen around 6 weeks in culture and establishment of electrical
activity around 9–15 weeks (Shi et al., 2012b; Kirwan et al.,
2015; Paavilainen et al., 2018). As the field progresses, it will be
necessary to determine an acceptable time frame for development
of these cultures, without sacrificing maturation and predictive
capabilities of convulsant drug effects.
FUNCTIONAL ANALYSIS OF
iPSC-DERIVED CULTURES
While there are now many emerging disease platforms and
investigative models using iPSC-derived neural cells, research
using human iPSC neural networks for the express purposes
of drug screening is still in its infancy. It has been shown
that iPSC-derived neurons respond appropriately to convulsants,
pro-convulsants, and conditions known to generate epileptiform
activity and as such, could be utilized in PSL testing (Odawara
et al., 2014, 2016b; Tukker et al., 2016, 2018; Ishii et al.,
2017; Kayama et al., 2018; Paavilainen et al., 2018). While
typical endpoints for current PSL tests include assessment
of biochemical, morphological and physiological endpoints,
the throughput capabilities of these assays are too low
for toxicity screening. Changes to ion channels, calcium
changes, and network responses are implicated in many
toxicity pathways and functional techniques used must be
able to detect these changes. Convulsant compounds affect
the nervous system and neuronal excitability as discussed in
Section “Inducing Seizure-Like Events Using in vitro Models.”
These disruptions in turn affect nervous system physiology,
often preceeding or occuring in the absence of the typical
morphological/biochemical changes. Furthermore, some existing
methods fail to record the most rapid events, such as
action potentials, or are not amenable to high-throughput
testing, making them less desirable for toxicity screening.
Therefore, methods used with iPSC-derived neural models must
demonstate a relatively high-throughput capability, without
compromising on the quality of the information obained.
Techniques enabling network-wide effects to be recorded and
visualized would provide relevant endpoints to monitor drug
induced SLEs.
In many cases, techniques such as patch clamping are
employed to monitor electrical activity and responses; however,
these are invasive and are traditionally limited to measurement of
a single cell. Patch clamping is also a very technically demanding
and precise method and requires a high level of expertise.
However, recent developments have enabled multiple-cell patch
clamping to be used in certain industrial applications (Vardi
et al., 2016). While patch clamping is a particularly efficient and
accurate method of studying ionic currents, its use for large-scale
toxicity screening is not practical.
Calcium Imaging
Fluorescent calcium imaging is a well-established technique
which enables visualization of free intracellular Ca2+ from
populations of cells. Calcium indicators are sensitive to calcium
movement and can be loaded in a non-invasive manner to
neuronal cells, although prolonged exposure to the dye is toxic.
Fluorescent dyes can either be single or multiple wavelength.
Calcium imaging enables the researcher to explore the role
calcium is playing in the cell, due to specific calcium-mediated
processes occuring over different time periods. For example,
calcium-mediated neurotransmitter release occurs much more
rapidly than calcium-mediated gene expression in the nucleus
(Grienberger and Konnerth, 2012). With regard to PSL, calcium
imaging can be used to detect electrical activity, oscillatory
activity, synchrony, and network activity, making it a very
useful tool for assessing neural circuitry and drug responses
(Smetters et al., 1999). This approach has been used in an
effort to characterize the development and maturation of
iPSC-derived neural calcium activity and to study network
responses to neurotransmitters/agents (Kirwan et al., 2015;
Tukker et al., 2016; Paavilainen et al., 2018). These studies
have demonstrated maturation of oscillatory calcium activity
and appropriate responses to a panel of agents. However, to
the authors knowledge, the use of calcium imaging for PSL
testing in iPSC-derived neural networks has not yet been
demonstrated. In contrast, the response of primary neural
cultures to a comprehensive panel of neurotransmitters and
convulsants has been shown by multi-well calcium imaging
(Pacico and Mingorance-Le Meur, 2014).
Recent advancements in the development of genetically
encoded calcium indicators (GECIs) removes the need
for fluorescent dye loading. GECIs, like their traditional
counterparts, are non-invasive, but can be targeted to specific
neurons (or astrocytes), allowing longer duration imaging,
without the risk of photo-toxicity (Mank and Griesbeck, 2008).
Other issues observed with fluorescent dyes such as background
fluorescence and non-specific dye loading can be overcome with
GECI technology (Mank and Griesbeck, 2008). Combining GECI
with iPSC-derived models could provide a new dimension to
PSL and arguably increase the throughput and efficiency of this
technique.
Multi-Electrode Array Recordings
Multi-electrode array (MEA) systems are increasingly used with
iPSC-derived cultures to assess spontaneous electrical activity,
synchronous epileptiform bursting activity, drug responses,
and network mechanisms, such as long-term potentiation and
depression (Odawara et al., 2014, 2016a,b; Frega et al., 2017;
Ishii et al., 2017; Seidel et al., 2017; Matsuda et al., 2018;
Tukker et al., 2018). MEAs take advantage of the generation
of neuronal ion currents. MEAs transduce this ionic voltage
change to electronic current, which can then be detected and
analyzed by a wide range of commerically available and custom-
made software. This technology is non-invasive, enabling the
real-time analysis of activity in multiple locations in cultured
neurons and also slices. They can record extracellular potentials
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and basic measures such as spiking and bursting activity and
network responses (Johnstone et al., 2010). The use of primary
rat cortical neurons on the MEA is well characterized, with
extensive neural activity endpoints. Multi-well MEAs have also
significantly increased the throughput capabilities of primary cell
culture assays. The parameters and results from primary models
are important for providing a comparative system for emerging
iPSC-derived MEA data (Bradley et al., 2018). A number of
studies have been carried out to determine whether MEA
analysis of iPSC-derived neural networks is a viable option for
toxicity screening. Furthermore, a broad panel of drugs have
been evaluated, and results suggest that MEAs are a useful tool
in screening compounds with diverse mechanisms of action
(McConnell et al., 2012; Valdivia et al., 2014; Kasteel and
Westerink, 2017).
As the throughput capabilities of MEAs increase and their
usage in toxicity screening becomes more widespread, it will
be important to generate standard protocols and definitions of
SLEs in iPSC-derived models. Recent studies have assessed a wide
variety of endpoints to demonstrate epileptiform activity and
network functionality, with primary rodent cells (Bradley et al.,
2018) and iPSC-derived neural co-cultures (Tukker et al., 2018).
While there are some commonalities between approaches, each
group using MEAs for neurotoxicity screening assess different
endpoints based upon their respective experimental design. For
example, a common endpoint groups consider is the number of
spikes in a burst, with bursts being typical of epileptiform activity.
Matsuda et al. (2018) have recently published a stepwise method
for detection of synchronized burst firings in iPSC-derived neural
cultures, which is a positive move toward standard protocols for
assessing epileptiform activity using the MEA (Matsuda et al.,
2018).
CULTURE MEDIUM AND
EXPERIMENTAL SOLUTION
CONSIDERATIONS
The first stage of any project to evolve a reliable protocol
for iPSC usage is to optimize the basic conditions for growth
and differentiation, as these conditions can influence structural
and functional endpoints. Growth media is the most important
determinant of these outcomes. Evidently, as the cellular culture
itself should be as representative of in vivo as possible, all
integrated factors such as the media should also aim to mimic
in vivo compositions. Multiple companies and institutions are
now producing their own media, leading to great variation within
the field. Many of these media are based on well-established
neurobasal and/or DMEM recipes (Shi et al., 2012a; Bardy et al.,
2015). Interestingly, it has been shown that concentrations of
salts (in particular, NaCl) and the presence of serum may directly
influence certain electrical activity (Bardy et al., 2015), which
creates another issue for functional imaging studies, as groups are
imaging their cells using different fluid compositions.
Artificial cerebrospinal fluid (aCSF) is a mimic of the fluid
surrounding the brain in vivo and contains the necessary salts
and pH to maintain cells and elicit functional recordings. Indeed,
aCSF is widely used for slice assays and primary cultures
and for inducing and assessing epileptiform activity. Due to
the range of medium available for iPSC culture, it may be
that a defined aCSF formulation should be used for calcium
imaging/MEA studies to create a standard protocol for iPSC-
derived neural toxicity testing. It is also possible to obtain
human cerebrospinal fluid (hCSF) from patients, which has been
shown to have a protective effect on resected human tissue,
promoting longevity compared with culture medium (Schwarz
et al., 2017). Furthermore, preservation of electrophysiological
properties, including network-level activity, is observed. While
it appears unlikely that hCSF would be readily available in the
quantities necessary to culture and assess iPSC-derived neural
models, it would nevertheless be interesting to determine what
effects, if any, this composition has on the electrophysiological
activity of the cultures.
INDUCING SEIZURE-LIKE EVENTS
USING IN VITRO MODELS
Existing assays used to study SLE manipulate cellular processes
in otherwise healthy tissue, in order to initiate seizurogenesis
and generate SLE. Seizurogenesis describes the generation of a
seizure, falling under the broad umbrella of epileptogenesis –
modifications in the brain to support seizure development. It is
likely that epileptogenic mechanisms occur before, throughout,
and following seizurogenesis to support seizure propagation,
leading to changes within the brain which are receptive
to seizurogenesis before a seizure occurs (Blauwblomme
et al., 2014). However, neither of these processes are entirely
understood and both seizurogenesis and epileptogenesis can arise
from multiple mechanisms, which adds increased complexity.
On the most elementary level, one can consider seizurogenesis
to be the result of perturbation to the delicate balance
between neuronal excitation and inhibition. Indeed, suppressing
inhibition and enhancing excitation are both criteria for epileptic
discharges (Lerche et al., 2001).
The induction of SLE is well-established in primary in vitro
models and brain slice assays, using agents which alter
ion flux, neurotransmission and affect the whole electrical
network (Yaari et al., 1983, 1986; Pena and Tapia, 2000;
Gabriel et al., 2004; Debanne et al., 2006; Easter et al., 2007;
Gonzalez-Sulser et al., 2011; Igelstrom et al., 2011; Accardi et al.,
2017). In order to generate a SLE, the system must exhibit typical
healthy processes and receptors/drug targets for the convulsants
to act upon. The following sections briefly describe some of the
common methods that have been used to induce SLE. These
can also be considered a prerequisite for a valid iPSC-derived
seizure-liability model.
Manipulating Ion Levels
Neuronal excitability is controlled by ion gradients. The
manipulation of ion levels in neurons can result in increased
activity and SLE. Changes to potassium, calcium, and magnesium
levels are typically achieved by modulation of the bathing
solution used to perfuse the cell/tissue for the experiment.
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Elevated extracellular potassium concentrations ([K+]e) can
lead to depolarization, increased firing, and burst firing,
all of which facilitate seizurogenesis. Furthermore, during
seizure, [K+]e increases and extracellular sodium and calcium
([Na+]e/[Ca2+]e) decreases, due to neuronal release and uptake,
respectively (Raimondo et al., 2015). This can create a cycle
of depolarization, promoting further AP discharge. Increasing
potassium levels is an established method for generating SLE
in vitro (Yaari et al., 1986; Traynelis and Dingledine, 1988).
Several studies have demonstrated that iPSC-derived neurons
can respond to high potassium solutions, with increases in
intracellular calcium observed (Tukker et al., 2016; Paavilainen
et al., 2018).
Lowering the extracellular concentration of Ca2+ can induce
regular SLE, accompanied by transient decreases in Na+ and
increases in K+ in the extracellular space (Yaari et al., 1983).
Low [Ca2+]e enhances neuronal excitability and can induce
spontaneous, synchronized bursts of activity, reminiscent of
epileptiform discharges. Calcium influx occurs via voltage
gated-calcium channels and N-methyl-D-aspartate (NMDA)
receptors and during seizure, the [Ca2+]e decreases far lower
than non-convulsing tissue (Simons, 1988; Somjen, 2002;
Blauwblomme et al., 2014). This decrease is due to calcium
influx into neurons undergoing the seizure activity, which
impairs synaptic transmission as there is too little Ca2+e to
sustain the calcium influx. Higher Ca2+e can enhance synaptic
transmission as calcium is available to enter the cell, even
though a higher [Ca2+]e reduces excitability (as the cell is not
depolarized). However, this remains to be observed in iPSC-
derived models.
Lowering the concentration of Mg2+ can affect the system
at the network level, leading to recurrent SLE (Igelstrom et al.,
2011; Pacico and Mingorance-Le Meur, 2014). Normal activity
is asynchronous, so for seizures to occur, multiple neurons
need to be recruited in an unusually hypersynchronous manner
(Vaughan and Delanty, 2002; Jiruska et al., 2013). The cerebral
cortex is prone to generating synchronous, large bursts of activity
which facilitates seizurogenesis (Bromfield et al., 2006). Bursts are
generated by sustained recurrent excitation, elicited by clusters of
glutamatergic pyramidal neurons in the cortex, and followed by
a period of hyperpolarization. Recurrent excitation via NMDA
and non-NMDA glutamatergic receptor activation can further
recruit and synchronize neurons into the seizurogenic activity
(McCormick and Contreras, 2001; Debanne et al., 2006). This
sequence of events is termed the paroxysmal depolarizing shift
(PDS). Normally, magnesium (Mg2+) blocks the pore of the
NMDA receptor. During the PDS, the membrane becomes
depolarized to the point where the voltage-dependent Mg2+
block of NMDA receptors is released. When Mg2+ is lowered,
NMDA receptors become permeable to Ca2+ which, alongside
voltage-gated Na+ activation, induces long-lasting potentiation
of glutamatergic transmission at pyramidal cell synapses (Staley
and Dudek, 2006). Activation of multiple NMDA receptors
further depolarizes the cell and promotes increased Ca2+ influx
(Vaughan and Delanty, 2002). Indeed, NMDA and AMPA
receptor antagonists are well-known to suppress seizurogenesis
(Rogawski, 1992).
Pharmacological Induction of
Seizure-Like Events
Seizure-like events can also be induced pharmacologically
in seizure models, with most agents promoting increased
bursts of activity from release of excitatory and inhibitory
neurotransmitters. Common GABA agonists such as
benzodiazepines and barbiturates are known to be anti-
convulsive and function by enhancing the inhibitory effect
of GABA (Wong, 2010). Similarly, antagonistic agents which
block GABA synthesis (such as isoniazid) are documented
pro-convulsants (Treiman, 2001).
An agent now used in the therapy of multiple sclerosis,
4-aminopyridine (4-AP), is an experimental compound also
widely used to induce SLE and increase neuronal activity in
rodent models (Pena and Tapia, 2000; Easter et al., 2007;
Gonzalez-Sulser et al., 2011; Hongo et al., 2015; Accardi et al.,
2017; Bradley et al., 2018; Kreir et al., 2018) and has been
shown to elicit recurrent depolarizations in human iPSC-derived
networks (Pruunsild et al., 2017; Matsuda et al., 2018). 4-AP
blocks transient K+ currents, prolonging action potentials by
inhibiting repolarization. As this can act on both glutamatergic
and GABAergic neurons, the release of GABA is reduced, leading
to excitation (Avoli, 2014).
GABA antagonism is a major mechanism of seizurogenesis,
as the inhibition of GABA’s inhibitory mode of action results in
increased excitation (Olsen et al., 1999). A variety of GABAA
receptor antagonists can be chosen to cause SLE. Commonly used
are: gabazine, picrotoxin, bicuculline, and pentylenetetrazole
(PTZ; Easter et al., 2007; Hongo et al., 2015; Bradley et al., 2018).
These agents have convulsant effects, with their mechanisms
not entirely understood. In the case of bicuculline, for example,
its ability to generate SLE comes from preventing Cl− influx,
which would normally result in hyperpolarization. Epileptiform
activity in iPSC-derived cultures has been observed following
treatment with bicuculline (Odawara et al., 2014, 2016b).
Although mainly used to induce SLE in vivo, PTZ can
also be used in vitro (Easter et al., 2009) and can induce
epileptiform burst firing in iPSC-derived cultures (Odawara
et al., 2016b). Picrotoxin has also been used in iPSC-derived
neural cultures to assess network activity (Kuijlaars et al., 2016)
and Gabazine to generate epileptiform activity (Ishii et al.,
2017).
FUTURE DIRECTIONS
The production of a robust, efficient, high-throughput human
assay for seizure-liability testing is an important contribution to
pre-clinical safety studies. While the progress in utilizing new
platforms such as iPSC-derived neural cultures for toxicity testing
has been impressive, there remain a number of hurdles that
still need to be overcome. Notably, the intricacy of the nervous
system cannot be completely modeled using only individual cell
types. The inclusion of multiple neuronal subtypes including
excitatory and inhibitory neurons, astrocytes, oligodendrocytes,
and microglia will add further complexity and relevance to model
systems.
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FIGURE 3 | Development of a three-dimensional (3D) neural organoid from IPSCs. (A) IPSCs can be spontaneously differentiated within 3D aggregates. (B) 3D
aggregates can be further cultured in 3D to develop a neural organoid. These neural organoids recapitulate the developmental processes and structural hierarchy
seen in the developing brain. (C) Section of the laminated structure formed within the neural organoid.
Reproducible Generation of Functionally
Mature Neurons
While human stem cell derived neurons can be routinely
produced using well established methods (Chambers et al.,
2009; Shi et al., 2012b) the reproducibility of these methods is
variable (Hu et al., 2010). The neurons produced are often slow
(2–3 months) to exhibit functional properties such as sustained
action potential firing and synaptic plasticity. This represents
a significant limitation in experimental models and screening
platforms. Alternative approaches such as transdifferentiation
allow the direct neuronal cell reprogramming to generate
different neuronal lineages, termed “induced neurons” (iN;
Vierbuchen et al., 2010) or “induced astrocytes” (iA; Caiazzo
et al., 2015). iN can be generated within 3–5 weeks after
reprogramming and demonstrate physiological action potential
firing (Vierbuchen et al., 2010). Furthermore, iA can be produced
within 2 weeks (Stasiukyniene et al., 2009; Caiazzo et al.,
2015). While these approaches have reduced the time required
to generate functional neuronal subtypes, the efficiency of
generating iN cells is often less than 10% (Yang et al., 2011).
2D vs 3D Culture
A criticism of the use of two-dimensional (2D) human cultures
is that they do not reproduce the structure and hierarchical
connectivity that is seen in three-dimensional (3D) tissue. An
important route to obtain better structural and morphological
relevance is to generate iPSC-derived 3D co-cultures such as
organoids and spheroids (Figure 3), which have been shown to
recapitulate early development of the human cortex (Lancaster
et al., 2013; Lancaster and Knoblich, 2014a,b; Pasca et al., 2015).
While these 3D cultures are useful models for early development
and diseased states, they are less able to model complex, later
stages of development and lack vasculature (Sun et al., 2018).
Overcoming these issues and applying this technology to seizure-
liability testing could provide an insight into not only the
mechanisms of seizure spread between layers of cortical cells, but
possibly identify novel targets and pharmaceuticals. The advent
of matured 3D structures would aim to generate layers of the
cortex as seen in vivo and provide a robust and relevant platform
that resembles a human cortex, in terms of both structure and
functionality, adding an extra dimension and increased relevance
for human seizure-liability testing.
Stability of Cultures and Long-Term
Recording
Current protocols for generating iPSC-derived neural cultures
demonstrate variability in the emergence of functional maturity
and cellular composition. Variability between iPSC lines from
different patients, as well as variability between closes from
the same patient, also represents a significant hurdle in the
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deployment of in vitro screening platforms (Cahan and Daley,
2013). Furthermore, the diversity of differentiation strategies
leads to differences in the ratio of cell types, such as neurons
and astrocytes, and raises questions over the validity of models
in representing human brain tissue. As such, standardization and
validation of differentiation protocols for specific applications
such as safety pharmacology testing should be considered.
Induced pluripotent stem cell-derived neurons represent a
fetal stage (Patani et al., 2012); hence, strategies to enhance the
functional maturity of cultures are under investigation (Bardy
et al., 2015). However, the ability to monitor the functional
maturation of neuronal networks in real time is an important
issue in the development of relevant model systems. While
methods such as MEA analysis can be used to non-invasively
monitor epileptiform phenomena, these systems offer relatively
low spatial resolution. However, optical imaging and stimulation
techniques can be employed to interrogate neuronal networks
at single-cell resolution (Afshar Saber et al., 2018) and offer the
opportunity to develop non-invasive, high-throughput screening
tools for monitoring seizure liability.
CONCLUSION
Over the past 20 years, the application of human iPSCs in drug
discovery and safety pharmacology has dramatically increased.
The increasing capabilities of iPSC-derived cell culture (in
both 2D and 3D) and high-throughput electrophysiological
techniques will hopefully provide researchers with the ability
to generate functional cell networks which are suited to
multiple safety pharmacology applications. In order to be
validated and accepted, PSL testing using human iPSCs
needs to satisfy the basic requirements for a predictive
model: they must express expected human cell types and
receptors, they must respond pharmacologically to a wide
range of compounds and conditions, and they must display
functionality at the single-cell and network level. Meeting all
of these criteria would lay the foundation for accepted and
robust methods in human drug discovery, which is not only
relevant to human systems, but also cost-effective and ethically
acceptable.
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